Celcuity 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Celcuity said 2026 was a transformative year as it transitioned to a commercial-stage company, with ReptorPick becoming commercially available in the U.S. on September 30th, 2026.
- Since launch, 78% of the top 36 strategic accounts had ordered ReptorPick; more than 3,400 sites had engaged with Celcuity oncology sales specialists, and more than 1,100 healthcare providers had attended ReptorPick educational programs.
- The company reported that 91% of U.S. commercial and Medicare lives were in healthcare plans covering Revtrupin, and that the treatment had been incorporated into 3 of the 4 largest healthcare provider pathways within 30 days of commercial availability.
- ReptorPick shipments began on September 30th at a wholesale acquisition cost of $10,000 per vial, or $30,000 per 28-day cycle; Celcuity reported no product revenue in the 3rd quarter of 2026 because no product reached treatment locations by September 30th.
- Celcuity reported a 3rd quarter 2026 net loss of $73.3 million, or $1.33 per share, compared with $43.8 million, or $0.92 per share, in the prior-year period; non-GAAP adjusted net loss was $66.8 million, or $1.21 per share, compared with $37.2 million, or $0.78 per share.
- Total operating expenses were $77.3 million, including research and development expenses of $37.5 million and selling, general, and administrative expenses of $39.8 million.
- Net cash used in operating activities was $66.2 million in the 3rd quarter of 2026; cash, cash equivalents, and short-term investments were $642.7 million at quarter-end.
- Celcuity made a $50 million payment to Pfizer following FDA approval, classified as investing activity, and reported that its June 2026 convertible note offering generated gross proceeds of $575 million and net proceeds of $557 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
This call is being recorded on Thursday, November 5, 2026. I would now like to turn the conference over to Marissa.
Please go ahead. Thank you, Marissa, and good afternoon, everyone.
Thank you for joining us to review Celcuity's third quarter 2026 financial results and business update. Earlier today, Celcuity Inc. released financial results for the quarter ended September 30, 2026. The press release can be found on the investor section of Celcuity's website. Joining me on the call today are Brian Sullivan, Celcuity's Chief Executive Officer and Co-Founder, Vicky Hahne, our Chief Financial Officer, as well as Igor Gorbatchevsky, our Chief Medical Officer, and Eldon Mayer, our Chief Commercial Officer, who will both be available for questions during Q&A. Before we begin, I would like to remind listeners that our comments today include some forward-looking statements. These statements involve a number of risks and uncertainties, which are outlined in today's press release and in our reports and filings with the SEC.
Actual events or results may differ materially from those projected in the forward-looking statements. Such forward-looking statements and their implications involve known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those projected. On this call, we also refer to non-GAAP financial measures. These non-GAAP measures are used by management to make strategic decisions, forecast future results, and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find a table reconciling the non-GAAP financial measures to GAAP measures in today's press release. With that, I would like to turn the call over to Brian Sullivan, CEO of Celcuity.
Please go ahead, Brian. Thank you, Jodi, and good afternoon, everyone.
Thank you for joining our third quarter 2026 operating and financial update conference call. 2026 has been a transformative year for Celcuity as we transition to a commercial stage company. REVTORPYK is now available to U.S. physicians to prescribe for use in combination with fulvestrant, with or without palbociclib, for the treatment of HR-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The unprecedented efficacy results and favorable safety profile reported from the PIK3CA wild-type cohort of the VIKTORIA-1 study provide physicians with a compelling rationale to utilize a gedatolisib regimen to address the significant unmet need for the tens of thousands of patients affected each year by advanced breast cancer.
We are pleased to report and provide our first update on the results of the foundational work our commercial and medical teams have been performing for the past two years to prepare for the commercial launch of REVTORPYK. Our launch is off to a great start, and results to date are all very encouraging. To provide insight into the effectiveness of our field team's launch activities, particularly since the drug became commercially available on September 30, we can share the following key metrics. Since REVTORPYK became commercially available on September 30, 78% of the top 36 strategic accounts have ordered REVTORPYK. These accounts treat roughly 50% of the total addressable patient population. Over 3,400 sites, many of which are affiliated with one of the top 36 strategic accounts, have directly engaged with Celcuity oncology sales specialists. These sites treat 82% of breast cancer patients.
Over 1,100 healthcare providers have attended REVTORPYK educational programs. Our market access and medical affairs teams have also been very effective. Their efforts have resulted in obtaining early and broad payer coverage and inclusion in major provider pathways so that nearly all eligible patients now have access to REVTORPYK. Within two weeks of approval, we obtained a preferred category 1 recommendation in the NCCN guidelines for the REVTORPYK triplet and doublet as a second-line treatment option for HR-positive, HER2-negative advanced breast cancer patients lacking a PIK3CA mutation. With this NCCN recommendation and the direct engagement of our team, it has had with nearly all U.S. payers over the past 18 months, 91% of U.S. commercial and Medicare lives are in healthcare plans that cover REVTORPYK.
Now, given the complexity of managing care for cancer patients, most healthcare providers adhere to treatment guidelines, most commonly referred to as treatment pathways, that provide guidance and recommendations for the physicians who work within a specific healthcare system or network. Inclusion in these pathways eliminates a critical potential barrier to physician utilization of a medicine, and this process can take, in some cases, up to 12 months. Our team, though, was able to get REVTORPYK incorporated in three of the four largest healthcare provider pathways within just 30 days of becoming commercially available. These results reflect the groundwork we have been laying for the past 24 months. During this period, we have engaged over 1,000 key opinion leaders and community breast cancer experts, key accounts, major oncology organizations, including GPOs, state societies, and special interest groups, as well as patient advocacy groups.
Our unbranded marketing campaign at pampathway.com drove awareness of the PAM pathway, with metrics that tracked well ahead of industry benchmarks. CME and third-party peer-to-peer programs and regional events have further increased levels of awareness about the importance of comprehensive PAM inhibition and the unmet need in the second-line setting. With the build-out of the commercialization infrastructure needed to support the successful launch of REVTORPYK completed, commercial launch activities for REVTORPYK commenced immediately after approval. Our 88 oncology sales specialists, who have an average of 24 years of industry experience, are calling on physicians, supporting installation of REVTORPYK order sets within the electronic health record systems of their accounts, and in-servicing infusion centers and pharmacies. Our strategic accounts, payer reimbursement, medical science liaison, and KOL-focused teams are following through on the groundwork they laid prior to REVTORPYK approval.
All of these efforts are designed to offer patients and providers with rapid access and seamless support. To enable treating physicians to obtain gedatolisib on behalf of their eligible patients after we received FDA approval and prior to commercial availability of REVTORPYK, Celcuity opened an expanded access program in mid-August. Now nearly all of the patients enrolled in this program have been transitioned to commercial product. Shipments of REVTORPYK began on September 30th at a wholesale acquisition cost of $10,000 per vial, or $30,000 per 28-day cycle of treatment. Published epidemiological data estimates there are 37,000 patients in the U.S. receiving second-line treatment for HR-positive, HER2-negative advanced breast cancer, and that based on the data from the VIKTORIA-1 trial, patients treated with the gedatolisib regimen in this setting will remain on therapy for an average of 10 treatment cycles.
Assuming net receipt of 80% of our $30,000 WAC price per cycle, we estimate the total addressable market for REVTORPYK in the second-line setting, including both PIK3CA wild-type and mutant patients, is approximately $9 billion annually. Most healthcare providers will order REVTORPYK through specialty distributors using buy-and-bill reimbursement. REVTORPYK is then drop-shipped directly to the treatment location, which is typical for infused therapies, rather than through specialty pharmacies. By selling the product through this channel, we do not obtain access to granular information such as the number of doctors prescribing or the number of patients receiving REVTORPYK. As a result, when we report sales results beginning next year, the data we will be able to provide will be limited to metrics such as gross and net sales, vials shipped, and market access-related metrics.
We expect to provide a flash report on fourth quarter sales in mid-January, and we look forward to providing further updates next year. I would like now to turn to an update on the status of our clinical development programs and recently reported data. Based on the positive data from the PIK3CA mutant cohort of the phase III VIKTORIA-1 study, we submitted a supplemental NDA to the FDA in third quarter of 2026. We expect to submit VIKTORIA-1 phase III data for both the wild-type and mutant cohorts to global regulatory authorities later this year or early next year. In October, updated results from the phase III VIKTORIA-1 study were presented in a late-breaking rapid oral presentation at ESMO.
Key results included median PFS of 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet, versus 9.1 months with alpelisib plus fulvestrant in patients who had no liver metastases. The hazard ratio for the gedatolisib triplet and doublet versus the alpelisib doublet was 0.46 and 0.71 respectively. This is a particularly important result since patients lacking liver mets represent approximately 70% of all patients treated in this setting, according to real-world analyses. Our results for patients with liver mets were also very favorable and consistent with the primary PFS analysis. For the gedatolisib triplet and doublet versus the alpelisib doublet, the hazard ratio was 0.47 and 0.38 respectively. The objective response rate for patients with evaluable disease, updated to include both confirmed and unconfirmed responders, was 59% and 43% for the gedatolisib triplet and doublet respectively, versus 33% for the alpelisib doublet.
For these patients, the median duration of response for the gedatolisib triplet and doublet was 19.4 and 27.8 months respectively, versus 7.5 months for alpelisib plus fulvestrant. The discontinuation rate for gedatolisib due to adverse events was 5% and 4% with the gedatolisib triplet and doublet respectively, compared to 19% for alpelisib plus fulvestrant. The gedatolisib treatment discontinuation rate for the mutant cohort was lower than was reported for the wild-type cohort. The higher discontinuation rate for the wild-type cohort versus the mutant cohort largely reflects the activity in one region early in the study that enrolled a significant proportion of patients in the first six months. Discontinuations fell in this region as physicians gained experience.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
